Vivo Capital, LLC
About Vivo Capital, LLC’s 13F portfolio
Vivo Capital, LLC is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Vivo Capital, LLC reported $1.1B across 47 US-listed positions (). Its largest position is Trevi Therapeutics Inc (TRVI) at 8.7% of the reported book, and its ten biggest holdings make up 52% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NASDAQ: TRVI Trevi Therapeutics Inc | — — | 8.7% | 5.1M | $95.0M |
| 2 | NASDAQ: PRAX Praxis Precision Medicines | — — | 8.3% | 271K | $90.8M |
| 3 | NASDAQ: ERAS Erasca Inc | — — | 6.9% | 4.1M | $75.6M |
| 4 | NASDAQ: AVBP Arrivent BioPharma Inc | — — | 5.3% | 1.7M | $58.4M |
| 5 | NASDAQ: ABVX Abivax SA - ADR | — — | 5.0% | 415K | $55.3M |
| 6 | NASDAQ: TNGX Tango Therapeutics Inc | — — | 3.9% | 1.4M | $43.1M |
| 7 | NASDAQ: CRVS Corvus Pharmaceuticals Inc | — — | 3.8% | 2.8M | $41.9M |
| 8 | NASDAQ: DRUG Bright Minds Biosciences Inc | — — | 3.6% | 557K | $39.1M |
| 9 | NASDAQ: SVA Sinovac Biotech Ltd. | — — | 3.5% | 5.9M | $38.2M |
| 10 | NASDAQ: TENX Tenax Therapeutics Inc | — — | 3.3% | 2.5M | $36.4M |
| 11 | NASDAQ: ACRS Aclaris Therapeutics, Inc. | — — | 3.2% | 6.7M | $35.4M |
| 12 | NASDAQ: DYN Dyne Therapeutics Inc | — — | 3.2% | 1.6M | $34.6M |
| 13 | NASDAQ: DNTH Dianthus Therapeutics Inc | — — | 3.2% | 354K | $34.5M |
| 14 | NYSE: ANRO Alto Neuroscience Inc | — — | 2.9% | 1.2M | $31.9M |
| 15 | NASDAQ: DBVT DBV Technologies SA | — — | 2.8% | 1.8M | $30.3M |
| 16 | NASDAQ: SABS SAB Biotherapeutics Inc | — — | 2.6% | 7.3M | $28.5M |
| 17 | NASDAQ: MLTX Moonlake Immunotherapeutics | — — | 2.5% | 1.4M | $27.3M |
| 18 | NASDAQ: LBRX LB Pharmaceuticals Inc | — — | 2.4% | 800K | $26.0M |
| 19 | NASDAQ: NERV Minerva Neurosciences Inc | — — | 2.2% | 4.3M | $24.0M |
| 20 | NASDAQ: DSGN Design Therapeutics Inc | — — | 2.1% | 1.6M | $23.3M |
| 21 | NASDAQ: ORIC Oric Pharmaceuticals Inc | — — | 1.8% | 1.8M | $20.0M |
| 22 | NASDAQ: CAMP CAMP4 Therapeutics Corporation | — — | 1.7% | 4.2M | $18.6M |
| 23 | NASDAQ: SNSE Faeth Therapeutics Inc | — — | 1.6% | 722K | $18.1M |
| 24 | NASDAQ: ACHV Achieve Life Sciences Inc. | — — | 1.6% | 2.8M | $18.0M |
| 25 | NASDAQ: CMPX Compass Therapeutics Inc | — — | 1.6% | 7.8M | $17.0M |
Showing 1–25 of 47 positions on this page reported in this 13F.
- Healthcare98%
- AddedAVBPArrivent BioPharma Inc+89.9%$58.4M
- AddedABVXAbivax SA - ADR+73.2%$55.3M
- AddedTENXTenax Therapeutics Inc+1100%$36.4M
- AddedACRSAclaris Therapeutics, Inc.+0.4%$35.4M
- AddedANROAlto Neuroscience Inc+16.7%$31.9M
- AddedMLTXMoonlake Immunotherapeutics+40.0%$27.3M
- NewACHVAchieve Life Sciences Inc.—$18.0M
- NewEDITEditas Medicine Inc—$11.5M
- NewODTXOdyssey Therapeutics Inc—$10.8M
- NewAURAAura Biosciences Inc—$8.3M
- ReducedPRAXPraxis Precision Medicines−20.0%$90.8M
- ReducedERASErasca Inc−66.0%$75.6M
- ReducedTNGXTango Therapeutics Inc−36.0%$43.1M
- ReducedDBVTDBV Technologies SA−30.8%$30.3M
- ReducedSABSSAB Biotherapeutics Inc−36.1%$28.5M
- ReducedCMPXCompass Therapeutics Inc−18.7%$17.0M
- ReducedUNCYUnicycive Therapeutics−69.3%$2.6M
- ReducedKTTAPasithea Therapeutics Corp−77.8%$240K
- SoldVRDNViridian Therapeutics Inc−100%—
- SoldCOGTCogent Biosciences Inc−100%—
Reading Vivo Capital, LLC’s 13F portfolio
Vivo Capital, LLC’s $1.1B 13F book is spread across 47 reported positions and is concentrated toward its biggest ideas, with the top ten holdings at 52%. The largest positions carry real weight, so how those names perform matters a lot to the overall book. Its five largest positions are TRVI, PRAX, ERAS, AVBP and ABVX, led by Trevi Therapeutics Inc (TRVI) at 8.7% of the portfolio. The heaviest sector exposure is Healthcare (98%).
What Vivo Capital, LLC changed last quarter
Between 2026-03-31 and Q2 2026, Vivo Capital, LLC was roughly balanced between buying and selling: it opened 7 new positions and added to 6 more, while trimming 8 and closing 6 outright. Against a 47-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was Arrivent BioPharma Inc (AVBP), and its biggest reduction was Praxis Precision Medicines (PRAX).
What a 13F does and doesn’t reveal
A 13F captures only Vivo Capital, LLC’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Vivo Capital, LLC is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Vivo Capital, LLC's profile on this page is built directly from those filings.
How current is the 13F data on Vivo Capital, LLC's page?
It reflects Vivo Capital, LLC's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Vivo Capital, LLC files its next quarterly report, this page refreshes automatically.
Can I see Vivo Capital, LLC's complete list of holdings?
This page highlights Vivo Capital, LLC's largest positions rather than all 47 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Vivo Capital, LLC's filings.
Does a 13F show everything Vivo Capital, LLC owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Vivo Capital, LLC's book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Vivo Capital, LLC made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

